Depot-based delivery systems for pro-angiogenic peptides: a review
Insufficient vascularization currently limits the size and complexity for all tissue engineering approaches. Additionally, increasing or re-initiating blood flow is the first step towards restoration of ischemic tissue homeostasis. However, no FDA approved pro-angiogenic treatments exist, despite th...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2015-07-01
|
| Series: | Frontiers in Bioengineering and Biotechnology |
| Subjects: | |
| Online Access: | http://journal.frontiersin.org/Journal/10.3389/fbioe.2015.00102/full |
| _version_ | 1818512746992369664 |
|---|---|
| author | Amy H. Van Hove Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit |
| author_facet | Amy H. Van Hove Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit |
| author_sort | Amy H. Van Hove |
| collection | DOAJ |
| description | Insufficient vascularization currently limits the size and complexity for all tissue engineering approaches. Additionally, increasing or re-initiating blood flow is the first step towards restoration of ischemic tissue homeostasis. However, no FDA approved pro-angiogenic treatments exist, despite the many pre-clinical approaches that have been developed. The relatively small size of peptides gives advantages over protein-based treatments, specifically with respect to synthesis and stability. While many pro-angiogenic peptides have been identified and shown promising results in vitro and in vivo, the majority of biomaterials developed for pro-angiogenic drug delivery focus on protein delivery. This narrow focus limits pro-angiogenic therapeutics as peptides, similar to proteins, suffer from poor pharmacokinetics in vivo, necessitating the development of controlled release systems. This review discusses pro-angiogenic peptides and the biomaterials delivery systems that have been developed, or that could easily be adapted for peptide delivery, with a particular focus on depot-based delivery systems. |
| first_indexed | 2024-12-10T23:51:23Z |
| format | Article |
| id | doaj.art-89b2958b56274cb7a4a08a63309a1b4b |
| institution | Directory Open Access Journal |
| issn | 2296-4185 |
| language | English |
| last_indexed | 2024-12-10T23:51:23Z |
| publishDate | 2015-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Bioengineering and Biotechnology |
| spelling | doaj.art-89b2958b56274cb7a4a08a63309a1b4b2022-12-22T01:28:45ZengFrontiers Media S.A.Frontiers in Bioengineering and Biotechnology2296-41852015-07-01310.3389/fbioe.2015.00102144156Depot-based delivery systems for pro-angiogenic peptides: a reviewAmy H. Van Hove0Danielle SW Benoit1Danielle SW Benoit2Danielle SW Benoit3Danielle SW Benoit4University of RochesterUniversity of RochesterUniversity of RochesterUniversity of Rochester Medical CenterUniversity of Rochester Medical CenterInsufficient vascularization currently limits the size and complexity for all tissue engineering approaches. Additionally, increasing or re-initiating blood flow is the first step towards restoration of ischemic tissue homeostasis. However, no FDA approved pro-angiogenic treatments exist, despite the many pre-clinical approaches that have been developed. The relatively small size of peptides gives advantages over protein-based treatments, specifically with respect to synthesis and stability. While many pro-angiogenic peptides have been identified and shown promising results in vitro and in vivo, the majority of biomaterials developed for pro-angiogenic drug delivery focus on protein delivery. This narrow focus limits pro-angiogenic therapeutics as peptides, similar to proteins, suffer from poor pharmacokinetics in vivo, necessitating the development of controlled release systems. This review discusses pro-angiogenic peptides and the biomaterials delivery systems that have been developed, or that could easily be adapted for peptide delivery, with a particular focus on depot-based delivery systems.http://journal.frontiersin.org/Journal/10.3389/fbioe.2015.00102/fullHydrogelsAngiogenesisDrug deliveryreviewBiomaterialsControlled Release |
| spellingShingle | Amy H. Van Hove Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit Danielle SW Benoit Depot-based delivery systems for pro-angiogenic peptides: a review Frontiers in Bioengineering and Biotechnology Hydrogels Angiogenesis Drug delivery review Biomaterials Controlled Release |
| title | Depot-based delivery systems for pro-angiogenic peptides: a review |
| title_full | Depot-based delivery systems for pro-angiogenic peptides: a review |
| title_fullStr | Depot-based delivery systems for pro-angiogenic peptides: a review |
| title_full_unstemmed | Depot-based delivery systems for pro-angiogenic peptides: a review |
| title_short | Depot-based delivery systems for pro-angiogenic peptides: a review |
| title_sort | depot based delivery systems for pro angiogenic peptides a review |
| topic | Hydrogels Angiogenesis Drug delivery review Biomaterials Controlled Release |
| url | http://journal.frontiersin.org/Journal/10.3389/fbioe.2015.00102/full |
| work_keys_str_mv | AT amyhvanhove depotbaseddeliverysystemsforproangiogenicpeptidesareview AT danielleswbenoit depotbaseddeliverysystemsforproangiogenicpeptidesareview AT danielleswbenoit depotbaseddeliverysystemsforproangiogenicpeptidesareview AT danielleswbenoit depotbaseddeliverysystemsforproangiogenicpeptidesareview AT danielleswbenoit depotbaseddeliverysystemsforproangiogenicpeptidesareview |